{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:24:23Z","timestamp":1793384663588,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Purpose:\u2002<\/jats:bold>\n                    In low\u2010 and middle\u2010income countries (LMICs), a large proportion of people with epilepsy do not receive treatment. An analysis of the availability, price, and affordability of antiepileptic drugs (AEDs) was conducted to evaluate whether these factors contribute to the treatment gap.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    Data for five AEDs (phenytoin, carbamazepine, valproic acid, phenobarbital, and diazepam) were obtained from facility\u2010based surveys conducted in 46 countries using the World Health Organization\/Health Action International (WHO\/HAI) methodology. Outcome measures were percentage availability, ratios of local prices to international reference prices, and number of days\u2019 wages needed by the lowest\u2010paid unskilled government worker to purchase treatment. Prices were adjusted for inflation\/deflation and purchasing power parity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Key Findings:\u2002<\/jats:bold>\n                    The average availability of generic AEDs in the public sector was &lt;50% for all medicines except diazepam injection. Private sector availability of generic oral AEDs ranged from 42.2% for phenytoin to 69.6% for phenobarbital. Public sector patient prices for generic carbamazepine and phenytoin were 4.95 and 17.50 times higher than international reference prices, respectively, whereas private sector patient prices were 11.27 and 24.77 times higher, respectively. For both medicines, originator brand prices were about 30 times higher. The highest prices were observed in the lowest income countries. The lowest\u2010paid government worker would need wages from 1\u20132.6\u2003days\u2019 to purchase a month\u2019s supply of phenytoin, whereas carbamazepine would cost 2.7\u201316.2\u2003days\u2019 wages. Despite its widespread use in LMICs, WHO\/HAI survey data for phenobarbital was only available from a small number of countries.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Significance:\u2002<\/jats:bold>\n                    In LMICs, availability and affordability of AEDs are poor and may be acting as a barrier to accessing treatment for epilepsy. Ensuring a consistent supply of AEDs at an affordable price should be a priority.\n                  <\/jats:p>","DOI":"10.1111\/j.1528-1167.2012.03446.x","type":"journal-article","created":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T09:33:50Z","timestamp":1332236030000},"page":"962-969","source":"Crossref","is-referenced-by-count":104,"title":["Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries"],"prefix":"10.1111","volume":"53","author":[{"given":"Alexandra","family":"Cameron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon L.","family":"Moshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje K.","family":"Mantel\u2010Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekhar","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61762-6"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.10.084327"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.52704.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.10-0100"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/475027a"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.12.019"},{"key":"e_1_2_9_8_1","unstructured":"Health Action International. (2010)Database of medicine prices availability affordability and price components. Available at:http:\/\/www.haiweb.org\/GlobalDatabase\/V2Prod\/[Accessed March 23 2011]."},{"key":"e_1_2_9_9_1","unstructured":"International Monetary Fund. (2007)World Economic Outlook Database. Available at:http:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2007\/01\/data\/index.aspx[Accessed March 23 2011]."},{"key":"e_1_2_9_10_1","unstructured":"International Monetary Fund.IMF Statistical Databases \u2013 Online Browsers and Documentation. Available at:http:\/\/www.imfstatistics.org\/imf\/[Accessed March 23 2011]."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/10898530-000000000-00000"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.12704.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan P","year":"2008","journal-title":"N Engl J Med"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.01805.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00425.x"},{"key":"e_1_2_9_16_1","volume-title":"International drug price indicator guide","author":"Management Sciences for Health","year":"2010"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01693.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.32800.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.09.064147"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.168"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318223c784"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02481.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900027358"},{"key":"e_1_2_9_24_1","first-page":"344","article-title":"The treatment of epilepsy in developing countries: where do we go from here?","volume":"79","author":"Scott RA","year":"2001","journal-title":"Bull World Health Organ"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67341-2"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-10-25"},{"key":"e_1_2_9_27_1","volume-title":"The global burden of disease: 2004 update","author":"WHO","year":"2008"},{"key":"e_1_2_9_28_1","unstructured":"WHO. (2009)Defined Daily Dose \u2013 Definition and general considerations. The WHO Collaborating Centre for Drug Statistics Methodology. 2009. Available at:http:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/[Accessed May 10 2011]."},{"key":"e_1_2_9_29_1","unstructured":"WHO. (2011)Model Lists of Essential Medicines. 17th List. Available at:http:\/\/whqlibdoc.who.int\/hq\/2011\/a95053_eng.pdf[Accessed May 10 2011]."},{"key":"e_1_2_9_30_1","volume-title":"Measuring medicine prices, availability, affordability and price components","author":"WHO, Health Action International","year":"2008"},{"key":"e_1_2_9_31_1","unstructured":"World Bank. (2011)Country Data. Available at:http:\/\/data.worldbank.org\/country[Accessed March 23 2011]."},{"key":"e_1_2_9_32_1","unstructured":"World Health Organization International League Against Epilepsy International Bureau for Epilepsy. (2005)Atlas: epilepsy care in the world. Available at:http:\/\/www.who.int\/mental_health\/neurology\/Epilepsy_atlas_r1.pdf[Accessed December 31 2011]."},{"key":"e_1_2_9_33_1","first-page":"273","volume-title":"International public health: diseases, programs, systems, and policies","author":"Yach D","year":"2006"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2012.03446.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2012.03446.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T08:36:08Z","timestamp":1698654968000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2012.03446.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1528-1167.2012.03446.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03446.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,20]]}}}